Disposition of Oxazepam in Patients on Maintenance Hemodialysis

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1984 Aug 16

PMID 6482312

Citations 2

Authors

H R Ochs

D J Greenblatt

U Klehr

Affiliations

Soon will be listed here.

Abstract

The pharmacokinetics of a single 30-mg oral dose of oxazepam was evaluated in seven patients with chronic renal failure on maintenance hemodialysis and in seven healthy controls matched for age and sex. Based on total (free plus bound) serum oxazepam concentrations, elimination half-life was prolonged in renal patients compared to controls (22 vs 8 h, p less than 0.001) and volume of distribution increased (3.0 vs 1.4 1/kg, p less than 0.02). However, total clearance was similar between groups (1.8 vs 1.9 ml/min per kilogram). These findings were confounded by the increased oxazepam free fraction in serum of renal failure patients (10.3%) as compared to healthy controls (4.3%). Correction for differences in binding indicates similar distribution of unbound oxazepam between groups, but reduced clearance of pharmacologically active unbound oxazepam in renal patients (18 vs 45 ml/min per kilogram). Oxazepam dosage, therefore, may require downward adjustment for renal failure patients on hemodialysis.

Citing Articles

Effect of cirrhosis and renal failure on the kinetics of clotiazepam.

Ochs H, Greenblatt D, Knuchel M Eur J Clin Pharmacol. 1986; 30(1):89-92.

PMID: 2872061 DOI: 10.1007/BF00614202.

Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.

Sennesael J, Verbeelen D, Vanhaelst L, Pirola R, Bareggi S Eur J Clin Pharmacol. 1991; 41(1):65-8.

PMID: 1782980 DOI: 10.1007/BF00280109.

References

Murray T, CHIANG S, Koepke H, Walker B . Renal disease, age, and oxazepam kinetics. Clin Pharmacol Ther. 1981; 30(6):805-9. DOI: 10.1038/clpt.1981.241. View

Ochs H, Greenblatt D, Kaschell H, Klehr U, Divoll M, Abernethy D . Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. Br J Clin Pharmacol. 1981; 12(6):829-32. PMC: 1401920. DOI: 10.1111/j.1365-2125.1981.tb01315.x. View

Odar-Cederlof I, Vessman J, Alvan G, Sjoqvist F . Oxazepam disposition in uremic patients. Acta Pharmacol Toxicol (Copenh). 1977; 40 Suppl 1(1):52-62. View

Greenblatt D . Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet. 1981; 6(2):89-105. DOI: 10.2165/00003088-198106020-00001. View

Ochs H, Greenblatt D, Otten H . Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr. 1981; 59(16):899-903. DOI: 10.1007/BF01721923. View

Greenblatt D, Divoll M, Harmatz J, Shader R . Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980; 215(1):86-91. View

Greenblatt D, Shader R, Abernethy D . Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983; 309(6):354-8. DOI: 10.1056/NEJM198308113090607. View

Greenblatt D, Franke K, Shader R . Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr. 1978; 146(2):311-20. View

Busch U, Molzahn M, Bozler G, KOSS F . Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease. Arzneimittelforschung. 1981; 31(9):1507-11. View

10.

Greenblatt D, Murray T, Audet P, Locniskar A, Koepke H, Walker B . Multiple-dose kinetics and dialyzability of oxazepam in renal insufficiency. Nephron. 1983; 34(4):234-8. DOI: 10.1159/000183022. View

11.

Ochs H, Rauh H, Greenblatt D, Kaschell H . Clorazepate dipotassium and diazepam in renal insufficiency: serum concentrations and protein binding of diazepam and desmethyldiazepam. Nephron. 1984; 37(2):100-4. DOI: 10.1159/000183222. View

12.

Moschitto L, Greenblatt D . Concentration-independent plasma protein binding of benzodiazepines. J Pharm Pharmacol. 1983; 35(3):179-80. DOI: 10.1111/j.2042-7158.1983.tb04302.x. View

13.

Grossman S, Davis D, Kitchell B, SHAND D, Routledge P . Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther. 1982; 31(3):350-7. DOI: 10.1038/clpt.1982.45. View